The Clinical Role of p-tau 181 and p-tau217 in Blood and CSF as Biomarkers for Alzheimer’s disease

Abstract

Amyloid-BETA plaques and neurofibrillary tangles made of hyperphosphorylated tau are pathological features of Alzheimer’s disease, the primary cause of dementia.phosphorylated tau at threonine 181 (p-tau-181) and threonine 217 (p-tau 217) are two tau isoforms that have become trustworthy fluid biomarkers for early  diagnosis ,disease surveillance ,and distinguishing one neurodegenerative illness from another. Cerobrospinal fluid (CSF) assays have given robust diagnostic value, whereas recent improvements in ultrasensitive plasma–based assays now enable minimally invasive and scalable detection.P-tau217 has been shown to have better sensitivity and specificity than p-tau 181,and it has a stronger correlation with tau  PET ,amyloid burden, and cognitive decline. P-tau indicators are increasingly seen as instruments for personalized and preventive therapy in addition to their diagnostic function. We suggest a digitally assisted, blood –first approach that incorporates plasma p-tau 217 with risk –tiered preventative treatments, remote cognitive monitoring, and two –cutoff triage techniques. This method makes it possible to identify at-risk persons earlier, lessens the need for intrusive CSF or expensive PET scans, and offers a target-to –target framework for therapeutic monitoring. Together,p-tau181 and p-tau 217 are transformational that have the potential to change AD prevention and precision care while also improving diagnostic accuracy.